Citadel Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-83,600
| Closed | -$3.32M | – | 13808 |
|
|
2026
Q1 | $3.32M | Buy |
83,600
+61,100
| +272% | +$1.56M | ﹤0.01% | 5066 |
|
|
2025
Q4 | $563K | Sell |
22,500
-9,100
| -29% | -$230K | ﹤0.01% | 8742 |
|
|
2025
Q3 | $766K | Sell |
31,600
-3,900
| -11% | -$69.3K | ﹤0.01% | 8131 |
|
|
2025
Q2 | $466K | Buy |
35,500
+18,400
| +108% | +$233K | ﹤0.01% | 8795 |
|
|
2025
Q1 | $246K | Buy |
17,100
+10,100
| +144% | +$165K | ﹤0.01% | 10024 |
|
|
2024
Q4 | $117K | Buy |
7,000
+1,100
| +19% | +$18.2K | ﹤0.01% | 11224 |
|
|
2024
Q3 | $94.3K | Sell |
5,900
-6,200
| -51% | -$76K | ﹤0.01% | 11196 |
|
|
2024
Q2 | $109K | Sell |
12,100
-5,600
| -32% | -$53.1K | ﹤0.01% | 10795 |
|
|
2024
Q1 | $200K | Buy |
17,700
+8,100
| +84% | +$76.7K | ﹤0.01% | 10318 |
|
|
2023
Q4 | $76.4K | Buy |
9,600
+2,600
| +37% | +$17.4K | ﹤0.01% | 11282 |
|
|
2023
Q3 | $45.3K | Buy |
7,000
+5,800
| +483% | +$39.7K | ﹤0.01% | 11861 |
|
|
2023
Q2 | $7.43K | Buy |
+1,200
| New | +$5.69K | ﹤0.01% | 13375 |
|
Citadel Advisors's CNTA Position: Q2 2026 in Review
Citadel Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 598,197 shares — an estimated $23.8M sold.
Citadel Advisors first reported a position in CNTA in Q2 2021 and held it in 18 quarters. The position peaked at $23.8M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Citadel Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 598,197 Centessa Pharmaceuticals shares in Q2 2026, an estimated $23.8M.
- Citadel Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 18 quarters.
- Citadel Advisors's Centessa Pharmaceuticals position peaked at $23.8M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.